Ex-Novartis gene therapy leader Otmane Boussif joins Anjarium

Anjarium Biosciences, a Swiss biotech focused on creating and delivering a new class of non-viral gene therapies, has announced the appointment of Otmane Boussif as chief technology officer (CTO).

Dr Boussif boasts more than 25 years of experience in shaping and leading biopharmaceutical technology development, bioprocessing, manufacturing, and regulatory requirements, across a range of biological modalities, with a strong focus on advanced cell and gene therapies.

He joins Anjarium from clinical-stage biotech company Sensorion (EPA: ALSEN), where he was also CTO. Prior to that, he spent six years at Swiss pharma giant Novartis (NOVN: VX) in various senior roles, including global head of cell and gene therapy technical development and global head of early phase development.